SOPHiA GENETICS (NASDAQ:SOPH) CTO Abhimanyu Verma Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $8.20, for a total value of $41,000.00. Following the sale, the chief technology officer directly owned 177,171 shares of the company’s stock, valued at approximately $1,452,802.20. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total transaction of $44,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.60, for a total transaction of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00.
• On Monday, July 6th, Abhimanyu Verma sold 5,285 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.10, for a total transaction of $26,953.50.
• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total transaction of $38,261.44.

SOPHiA GENETICS Stock Performance

Shares of SOPHiA GENETICS stock opened at $8.53 on Thursday. The stock’s fifty day simple moving average is $6.39 and its 200 day simple moving average is $5.40. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company has a market capitalization of $715.58 million, a PE ratio of -7.42 and a beta of 0.96. SOPHiA GENETICS SA has a 12 month low of $3.10 and a 12 month high of $8.85.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. On average, research analysts predict that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SOPH. HC Wainwright increased their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus target price of $10.00.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: The stock reached a new 12-month high, signaling strong recent momentum and investor interest. SOPHiA GENETICS Sets New 12-Month High
• Neutral Sentiment: Reported short interest was zero shares as of August 25, implying no measurable short-selling pressure. The data also showed no meaningful change from the prior period, limiting its usefulness as a trading signal.
• Negative Sentiment: CTO Abhimanyu Verma sold 5,000 shares for approximately $44,000 on August 24, reducing his position by 2.82%. Because the sale followed a pre-arranged Rule 10b5-1 plan, it may not reflect a current change in the executive’s outlook. SEC Form 4 filing
• Negative Sentiment: Director Kathy L. Hibbs sold 6,250 shares worth about $54,250 on August 25, decreasing her holdings by 5.71%. The sale adds to near-term insider-selling concerns but was also executed under a 10b5-1 plan. SEC Form 4 filing
• Negative Sentiment: Insider Philippe Menu sold 5,000 shares for approximately $43,400 on August 25, reducing his position by 2.29%. The transaction was pre-planned, which moderates—but does not eliminate—the potential negative signal from multiple insider sales. SEC Form 4 filing

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC increased its holdings in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. AWM Investment Company Inc. bought a new stake in SOPHiA GENETICS during the second quarter worth $9,809,000. Principal Financial Group Inc. raised its position in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares in the last quarter. Finally, Archon Capital Management LLC lifted its stake in SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after acquiring an additional 14,342 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.